Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 3/20 | 0.47 |
| ▸ | GLB1 | P16278 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032789 | 0.90 | EPHX2 (0.57) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL30632892 | 0.90 | EPHX2 (0.59) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL12961986 | 0.85 | EDNRA (0.61) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL14828737 | 0.83 | EDNRA (0.52) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL18131884 | 0.83 | EPHX2 (0.64) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL21000152 | 0.83 | EPHX2 (0.64) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL10132110 | 0.82 | EDNRA (0.62) | EDNRAHDAC4HDAC10HDAC6HDAC5 | |
| SCHEMBL16316424 | 0.82 | HDAC4 (0.65) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| Silver SCHEMBL18131892 | 0.81 | EPHX2 (0.61) | EDNRAEPHX2PTGS2HDAC4HDAC10 | |
| SCHEMBL12058681 | 0.81 | EPHX2 (0.61) | EDNRAEPHX2PTGS2HDAC4HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158063-A1 | Compounds, Compositions and Methods Related to PPAR Antagonists | GEORGETOWN UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012027482-A2 | COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO PPAR ANTAGONISTS | GEORGETOWN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158063-A1 | Compounds, Compositions and Methods Related to PPAR Antagonists | PPARG, PPARA, PPARD | EDNRA 902/4885EPHX2 2776/4885PTGS2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.